1. Dening J, Rao S, Thomas S, Prestidge CA (2016) Oral nanomedicine approaches for the treatment of psychiatric illnesses. J Cont Rel. https://doi.org/10.1016/j.jconrel.2015.12.047
2. Schizophrenia, WHO (2018) http://www.who.int/news-room/fact-sheets/detail/schizophrenia. Schizophrenia (last assessed: 19 September, 2018).
3. Citrome L (2011) Lurasidone for schizophrenia, a brief review of a new second generation antipsychotic. Clin Schiz Rel Psych 4(4):251–257
4. Jangipuria F, Londhe V (2015) Solubility enhancement of lurasidone hydrochloride by preparing SMEEDS. Int J Pharm Pharm Sci 7(11):283–288
5. Londhe YV, Deshmane BA, Singh RS et al (2018) Lurasidone β-cyclodextrin complexes, physicochemical characterization and comparison of their antidepressant, antipsychotic activities against that of self- microemulsifying formulation. J Mol Struct 17:1–19